6/3
08:00 am
urgn
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
5/20
08:18 am
urgn
UroGen Pharma Ltd. (
NASDAQ: URGN) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.
Low
Report
UroGen Pharma Ltd. (
NASDAQ: URGN) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.
5/18
08:00 am
urgn
UroGen Pharma to Present at Upcoming Investor Conferences
Medium
Report
UroGen Pharma to Present at Upcoming Investor Conferences
5/16
02:50 pm
urgn
UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO®, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer
Low
Report
UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO®, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer
5/13
08:00 am
urgn
UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual Meeting
Medium
Report
UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual Meeting
5/10
04:46 pm
urgn
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2022 Results - Earnings Call Transcript [Seeking Alpha]
Medium
Report
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2022 Results - Earnings Call Transcript [Seeking Alpha]
5/10
09:00 am
urgn
UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments
Medium
Report
UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments
5/6
09:39 am
urgn
UroGen Pharma Ltd. (
NASDAQ: URGN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.
Low
Report
UroGen Pharma Ltd. (
NASDAQ: URGN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.
5/3
08:00 am
urgn
UroGen Pharma to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
Low
Report
UroGen Pharma to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
4/30
09:38 am
urgn
UroGen Pharma Ltd. (
NASDAQ: URGN) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.
Medium
Report
UroGen Pharma Ltd. (
NASDAQ: URGN) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.
4/27
07:41 am
urgn
UroGen Pharma Ltd. (
NASDAQ: URGN) is now covered by analysts at Berenberg Bank. They set a "buy" rating on the stock.
Low
Report
UroGen Pharma Ltd. (
NASDAQ: URGN) is now covered by analysts at Berenberg Bank. They set a "buy" rating on the stock.
4/20
10:51 am
urgn
UroGen Pharma Ltd. (
NASDAQ: URGN) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.
Medium
Report
UroGen Pharma Ltd. (
NASDAQ: URGN) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.
4/13
11:06 am
urgn
UroGen Pharma Ltd. (
NASDAQ: URGN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.
Low
Report
UroGen Pharma Ltd. (
NASDAQ: URGN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.
4/6
10:21 am
urgn
UroGen Pharma Ltd. (
NASDAQ: URGN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.
Neutral
Report
UroGen Pharma Ltd. (
NASDAQ: URGN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.